Philips Teams up with Genomic Health to Utilize Innovative Digital Pathology Solutions

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a leader in the digitization of pathology, announced a collaboration with Genomic Health, Inc. (NASDAQ: GHDX), a world leading provider of genomic-based diagnostic tests, to leverage Philips' digital pathology tools in Genomic Health’s continuing scale up of its molecular diagnostic testing processes.

Pathology involves the examination of patient tissue samples and plays a crucial role in the diagnosis and treatment of a wide variety of diseases, including cancer. Philips is a pioneer and leader in the digitization of pathology. Pathologic evaluation of tumor tissue specimens is a critical step in the genomic testing process conducted by Genomic Health's Clinical Reference Laboratory. These genomic tests support physicians’ ability to deliver personalized treatment for patients diagnosed with complex disease such as cancer.

"Digitization has the potential to open new opportunities for increased efficiency and a reduction in the shortcomings of a traditional analog histopathology workflow," said Russell Granzow, General Manager of Philips Digital Pathology Solutions. "Philips is driving the evolution towards unified patient data to ensure pathologists are empowered to meet the increasing demand in cancer care for more precise diagnostics."

"By utilizing Philips’ latest digital pathology solution, we are providing our pathologists with a state-of-the-art system that will provide the next level of scalability and efficiency for our overall pre-analytical process, adding new capabilities that will be increasingly important as worldwide demand for Genomic Health's tests continues to grow," said Jon Cassel, Senior Vice President of Operations at Genomic Health.

Philips' lntelliSite Pathology Solution* is an automated digital pathology image creation, management and analysis system comprised of an ultra-fast pathology slide scanner, an image management system and case viewer. This solution is complemented by advanced software tools to manage the scanning, storage, presentation, research analysis and sharing of information.

* In the European Union, the Philips IntelliSite Pathology Solution is CE Marked under the European Union's 'In Vitro Diagnostics Directive' for in vitro diagnostic use.In Canada, the Philips IntelliSite Pathology Solution is licensed by Health Canada for in vitro diagnostic use. In the United States, the Philips IntelliSite Pathology Solution can be used for in vitro diagnostic use for Manual Read of the Digital HER2 Application and is available for research use only. The Philips IntelliSite Pathology Solution is registered for in vitro diagnostic use in Singapore and Middle East.

Related news articles:

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 106,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare.

Most Popular Now

Philips Foundation 2024 Annual Report: E…

Marking its tenth anniversary, Philips Foundation released its 2024 Annual Report, highlighting a year in which the Philips Foundation helped provide access to quality healthcare for 46.5 million people around...

New AI Transforms Radiology with Speed, …

A first-of-its-kind generative AI system, developed in-house at Northwestern Medicine, is revolutionizing radiology - boosting productivity, identifying life-threatening conditions in milliseconds and offering a breakthrough solution to the global radiologist...

Scientists Argue for More FDA Oversight …

An agile, transparent, and ethics-driven oversight system is needed for the U.S. Food and Drug Administration (FDA) to balance innovation with patient safety when it comes to artificial intelligence-driven medical...

New Research Finds Specific Learning Str…

If data used to train artificial intelligence models for medical applications, such as hospitals across the Greater Toronto Area, differs from the real-world data, it could lead to patient harm...

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

AI Agents for Oncology

Clinical decision-making in oncology is challenging and requires the analysis of various data types - from medical imaging and genetic information to patient records and treatment guidelines. To effectively support...

Patients say "Yes..ish" to the…

As artificial intelligence (AI) continues to be integrated in healthcare, a new multinational study involving Aarhus University sheds light on how dental patients really feel about its growing role in...

Brains vs. Bytes: Study Compares Diagnos…

A University of Maine study compared how well artificial intelligence (AI) models and human clinicians handled complex or sensitive medical cases. The study published in the Journal of Health Organization...

'AI Scientist' Suggests Combin…

An 'AI scientist', working in collaboration with human scientists, has found that combinations of cheap and safe drugs - used to treat conditions such as high cholesterol and alcohol dependence...

Start-ups in the Spotlight at MEDICA 202…

17 - 20 November 2025, Düsseldorf, Germany. MEDICA, the leading international trade fair and platform for healthcare innovations, will once again confirm its position as the world's number one hotspot for...